VictorMoyoMD
Oncology • Farmington, CTSpecialist in hematology & oncology, currently treats patients in Farmington, Connecticut.
Dr. Moyo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
NA
Farmington, CT 06030Phone+1 860-679-2100Fax+1 860-679-4815- Is this information wrong?
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2000 - 2002- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1999 - 2000
George Washington UniversityResidency, Internal Medicine, 1996 - 1999
University of Zimbabwe Huggins SOMClass of 1991
Certifications & Licensure
PA State Medical License 2008 - 2014
Clinical Trials
- Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer Start of enrollment: 2010 Jun 01
- Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer Start of enrollment: 2011 Mar 01
Publications & Presentations
PubMed
- 7 citationsLiposomal encapsulation of trans-crocetin enhances oxygenation in patients with COVID-19-related ARDS receiving mechanical ventilation.Paul-Michel Mertes, Olivier Collange, Pierre Coliat, Mainak Banerjee, Marie-Charlotte Diringer, Anne Roche, Xavier Delabranche, Vitaliy Chaban, Manon Voegelin, Alexand...> ;Journal of Controlled Release. 2021 Jun 24
- 53 citationsSafety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-...Pamela N. Munster, Ian E. Krop, Patricia LoRusso, Cynthia X. Ma, Barry A. Siegel, Anthony F. Shields, István Molnár, Thomas Wickham, Joseph G. Reynolds, Karen Campbell...> ;British Journal of Cancer. 2018 Oct 26
- 197 citations64Cu-MM-302 positron emission tomography quantifies variability of enhanced permeability and retention of nanoparticles in relation to treatment response in patients w...Helen Lee, Anthony F. Shields, Barry A. Siegel, Kathy D. Miller, Ian E. Krop, Cynthia X. Ma, Patricia LoRusso, Pamela N. Munster, Karen Campbell, Daniel F. Gaddy, Shan...> ;Clinical Cancer Research. 2017 Aug 1
- Join now to see all
Press Mentions
L.E.A.F. Pharmaceuticals Lead Investigational Product for Lung and Colorectal Cancers, LEAF-1401, Featured at the 2020 Virtual Annual Meeting of the American Society of Clinical Oncology (ASCO)June 10th, 2020
L.E.A.F. Pharmaceuticals Receives Positive US FDA Feedback and Comprehensive Roadmap for Clinical Development as Well as Registration of Its Four Lead Novel Anticancer DrugsOctober 30th, 2018
Grant Support
- Antigenics Renal CarcinomaNational Center For Research Resources2004
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
